• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Extended-Release Niacin Therapy and Risk of Ischemic Stroke in Patients With Cardiovascular Disease: The Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides: Impact on Global Health Outcome (AIM-HIGH) Trial Major Clinical Trials
Conclusions— Although there were numerically more ischemic strokes with addition of ERN to simvastatin that reached nominal significance, the number was small, and multivariable analysis accounting for known risk factors did not support a significant association between niacin and ischemic stroke risk. Clinical Trial Registration— URL: http://www.clinicaltrials.gov. Unique identifier: NCT00120289.
Source: Stroke - September 23, 2013 Category: Neurology Authors: Teo, K. K., Goldstein, L. B., Chaitman, B. R., Grant, S., Weintraub, W. S., Anderson, D. C., Sila, C. A., Cruz-Flores, S., Padley, R. J., Kostuk, W. J., Boden, W. E., on behalf of the AIM-HIGH Investigators Tags: Secondary prevention, Risk Factors, Acute Cerebral Infarction, Other Stroke Treatment - Medical Major Clinical Trials Source Type: research

The Current State of Niacin in Cardiovascular Disease Prevention A Systematic Review and Meta-Regression
ConclusionsThe consensus perspective derived from available clinical data supports that niacin reduces CVD events and, further, that this may occur through a mechanism not reflected by changes in high-density lipoprotein cholesterol concentration.
Source: Journal of the American College of Cardiology: Cardiovascular Interventions - January 21, 2013 Category: Cardiology Source Type: research

The Current State of Niacin in Cardiovascular Disease Prevention: A Systematic Review and Meta-Regression
Conclusions: The consensus perspective derived from available clinical data supports that niacin reduces CVD events and, further, that this may occur through a mechanism not reflected by changes in high-density lipoprotein cholesterol concentration.
Source: Journal of the American College of Cardiology - December 26, 2012 Category: Cardiology Authors: Paul M. Lavigne, Richard H. Karas Tags: Cardiometabolic Risk Source Type: research

Relationship of Lipoproteins to Cardiovascular Events The AIM-HIGH Trial (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides and Impact on Global Health Outcomes)
This study sought to examine the relationship between niacin treatment, lipoproteins, and cardiovascular (CV) outcomes in this secondary analysis of the AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides and Impact on Global Health Outcomes) trial.BackgroundDuring a 3-year follow-up in 3,414 patients with established CV disease and low high-density lipoprotein cholesterol (HDL-C) levels, combined niacin + low-density lipoprotein cholesterol (LDL-C)–lowering therapy did not reduce CV events compared with LDL-C–lowering therapy alone.MethodsSubjects taking simvastatin and/or ez...
Source: Journal of the American College of Cardiology: Cardiovascular Interventions - October 14, 2013 Category: Cardiology Source Type: research

Relationship of Lipoproteins to Cardiovascular Events: The AIM-HIGH Trial (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides and Impact on Global Health Outcomes)
This study sought to examine the relationship between niacin treatment, lipoproteins, and cardiovascular (CV) outcomes in this secondary analysis of the AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides and Impact on Global Health Outcomes) trial.Background: During a 3-year follow-up in 3,414 patients with established CV disease and low high-density lipoprotein cholesterol (HDL-C) levels, combined niacin + low-density lipoprotein cholesterol (LDL-C)–lowering therapy did not reduce CV events compared with LDL-C–lowering therapy alone.Methods: Subjects taking simvastatin and/o...
Source: Journal of the American College of Cardiology - August 2, 2013 Category: Cardiology Authors: John R. Guyton, April E. Slee, Todd Anderson, Jerome L. Fleg, Ronald B. Goldberg, Moti L. Kashyap, Santica M. Marcovina, Stephen D. Nash, Kevin D. O'Brien, William S. Weintraub, Ping Xu, Xue-Qiao Zhao, William E. Boden Tags: Cardiometabolic Risk Source Type: research

A systematic review of randomized clinical trials on the efficacy and safety of pitavastatin
Conclusion The FDA proven indications of pitavastatin are primary dyslipidemia and mixed dyslipidemia as adjunctive therapy to dietary changes to lower total cholesterol, LDL-C, apolipoprotein B (Apo B), triglycerides (TG), and to increase HDL-C. Pitavastatin might be suitable for subjects with diabetes, ACS (reduced revascularization), metabolic syndrome, CKD, HIV, and subjects with low levels of HDL-C. We highly recommend rational individualization for the selection of statin.PMID:35642121 | DOI:10.2174/2772432817666220531115314
Source: Pharmacological Reviews - June 1, 2022 Category: Drugs & Pharmacology Authors: Asim Ahmed Elnour Judit Don Azza Ramadan Adel Sadeq Abdulla Al Amoodi Kishore Gnana Sam Nadia Al Mazrouei Mohamed A Baraka Farah Hamad Farah Maisoun Alkaabi Source Type: research